QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF For Our Patients Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Beckey, C. Articles by Lutfi, N. Search for Related Content PubMed PubMed Citation Articles by Beckey, C. Articles by Lutfi, N.

NEW DRUG DEVELOPMENTS

Lercanidipine in the Treatment of Hypertension

Assistant Professor of Pharmacy Practice, College of Pharmacy, Nova Southeastern University, Palm Beach Gardens, FL

Amber Lundy, PharmD

Primary Care Clinical Pharmacist, Veterans Affairs Medical Center, Pharmacy Service (119), West Palm Beach, FL

Nahla Lutfi, PharmD

Primary Care Clinical Pharmacist, Veterans Affairs Medical Center, Pharmacy Service (119), West Palm Beach

Reprints: Dr. Beckey, College of Pharmacy, Nova Southeastern University, 3970 RCA Blvd., Ste. 7006, Palm Beach Gardens, FL 33410, fax 561/622-9205, cbeckey{at}nsu.nova.edu

OBJECTIVE: To review the literature regarding the efficacy, tolerability, and utility of lercanidipine in the treatment of hypertension.

DATA SOURCES: A search of the literature was performed using MEDLINE (1966-September 2006), EMBASE Drugs and Pharmacology (1980-September 2006), and Current Contents/Clinical Medicine (week 24, 2005-week 30, 2006). Package inserts from lercanidipine, nifedipine, felodipine, and amlodipine were also reviewed for comparison of adverse effects.

STUDY SELECTION AND DATA EXTRACTION: Articles were limited to clinical trials, abstracts, and review articles published in English.

DATA SYNTHESIS: Lercanidipine is a novel dihydropyridine (DHP) calcium-channel blocker indicated for the treatment of mild-to-moderate hypertension. Although it is not yet available in the US, lercanidipine has been utilized extensively in other countries. In 2 randomized controlled trials of approximately 400 patients with mild-to-moderate hypertension, lercanidipine showed efficacy similar to that of 2 other DHPs, felodipine and slow-release nifedipine, in significantly reducing systolic blood pressure and diastolic blood pressure (DBP) after 4 weeks. In a longer trial (12 mo), lercanidipine 10 mg/day led to normalized blood pressure in 49% of patients after 4 weeks. A postmarketing trial of 9050 patients corroborated the results observed in previous clinical trials, with 64% of patients achieving a DBP of less than 90 mm Hg and 32% attaining blood pressure control (<140/90 mm Hg). In elderly patients, lercanidipine was found comparable with lacidipine and nifedipine, showing similar decreases in DBP when compared with nifedipine (-18.3 vs -17.7 mm Hg, respectively). What distinguishes lercanidipine from other members of the DHP class is its lower incidence of adverse effects, particularly edema. One study showed that fewer patients withdrew secondary to adverse drug reactions in the lercanidipine (0.9%) and nifedipine (3.8%) group compared with the felodipine (4.5%) group. Lercanidipine has also shown efficacy similar to that of other antihypertensives, including atenolol, captopril, and losartan.

CONCLUSIONS: Lercanidipine may be an option in the treatment of hypertension, as current literature suggests comparable antihypertensive efficacy and better tolerability. Further randomized, double-blind clinical trials must be conducted in order to clarify its position among other antihypertensive medications.

Key Words: calcium-channel blocker, dihydropyridine, hypertension, lercanidipine

Published Online, March 6, 2007. www.theannals.com, DOI 10.1345/aph.1H299